Last reviewed · How we verify
NCT05276271
The Effect of Levetiracetam on Lipid Profile in Children
trial testing the blood sample test results in Epilepsy in 91 participants. Completed in 31 October 2021.
1 October 2021
Quick facts
| Lead sponsor | Ege University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 91 |
| Start date | 1 October 2020 |
| Primary completion | 1 October 2021 |
| Estimated completion | 31 October 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- the blood sample test results
Conditions studied
- Epilepsy — all drugs for Epilepsy →
- Child, Only — all drugs for Child, Only →
- Thyroid — all drugs for Thyroid →
- Lipid Disorder — all drugs for Lipid Disorder →
Sponsor
Ege University
Who can join
Adults 1 to 18, any sex, with Epilepsy or Child, Only. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Levetiracetam is a widely prescribed antiseizure medication in epileptic children due to an estimated better safety profile and easy accessibility. There is limited and contradicting data about the effect of levetiracetam on serum lipid metabolisms, especially in epileptic children. The aim of our study was to evaluate the effect of levetiracetam therapy on lipid metabolism in euthyroid non-obese epileptic children. In this case-control study, the investigators recruited 37 epileptic children receiving levetiracetam monotherapy for at least 12 months and 54 healthy controls. All the participants were euthyroid and within normal nutritional status limits for their age. Fasting blood samples were obtained for serum thyroid-stimulating hormone (TSH), free triiodothyronine, free thyroxine, total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, Triglyceride/HDL Index, uric acid, CRP, and transaminases at the administration. The investigators would like to show if epileptic children with levetiracetam monotherapy are susceptible to lipid metabolism alterations.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05276271
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other Ege University trials
Trials by the same sponsor.
- NCT07468227 — Effect of Helfer Skin Tap and Vibration on Pain and Fear in Children During Intramuscular Injection · NA · not yet recruiting
- NCT07473050 — Virtual Reality-Based 'Health at My Feet' Program for Individuals With Type 2 Diabetes · NA · not yet recruiting
- NCT06955338 — Music and VR Effects on Pain, Anxiety, and Fear During Oral Mucositis Care in Leukaemic Children · NA · not yet recruiting
- NCT07344532 — Effect of Preoperative Abdominal Effleurage on Postoperative Constipation · NA · not yet recruiting
- NCT07417748 — Kinesthetic Exercises on Adults · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05276271 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ege University
- Last refreshed: 11 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05276271.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing